BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND ZNF198, Q9UBW7, SCLL, RAMP, MYM, FIM, 7750 AND Prognosis
13 results:

  • 1. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
    Stilgenbauer S; Tausch E; Roberts AW; Davids MS; Eichhorst B; Hallek M; Hillmen P; Schneider C; Schetelig J; Böttcher S; Kater AP; Jiang Y; Boyer M; Popovic R; Ghanim MT; Moran M; Sinai WJ; Wang X; Mukherjee N; Chyla B; Wierda WG; Seymour JF
    Blood Adv; 2024 Apr; 8(8):1992-2004. PubMed ID: 38290108
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
    de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
    Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
    Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
    Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Davids MS; Rogers KA; Tyekucheva S; Wang Z; Pazienza S; Renner SK; Montegaard J; Ihuoma U; Lehmberg TZ; Parry EM; Wu CJ; Jacobson CA; Fisher DC; Thompson PA; Brown JR
    Blood; 2022 Feb; 139(5):686-689. PubMed ID: 34788401
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a fim study.
    Luque Paz D; Riou J; Verger E; Cassinat B; Chauveau A; Ianotto JC; Dupriez B; Boyer F; Renard M; Mansier O; Murati A; Rey J; Etienne G; Mansat-De Mas V; Tavitian S; Nibourel O; Girault S; Le Bris Y; Girodon F; Ranta D; Chomel JC; Cony-Makhoul P; Sujobert P; Robles M; Ben Abdelali R; Kosmider O; Cottin L; Roy L; Sloma I; Vacheret F; Wemeau M; Mossuz P; Slama B; Cussac V; Denis G; Walter-Petrich A; Burroni B; Jézéquel N; Giraudier S; Lippert E; Socié G; Kiladjian JJ; Ugo V
    Blood Adv; 2021 Mar; 5(5):1442-1451. PubMed ID: 33666653
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
    Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
    BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic leukemia.
    Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
    N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Biphenotypic hematologic malignancy: a case report of the 8p11 myeloproliferative syndrome in a child.
    Chen X; Zhang Y; Li Y; Lei P; Zhai Y; Liu L
    J Pediatr Hematol Oncol; 2010 Aug; 32(6):501-3. PubMed ID: 20562652
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. 8p11 myeloproliferative syndrome: a review.
    Jackson CC; Medeiros LJ; Miranda RN
    Hum Pathol; 2010 Apr; 41(4):461-76. PubMed ID: 20226962
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Rapid transformation of atypical myeloproliferative disorder with consistent t(8;13) to B-cell acute lymphoblastic leukemia: a case report.
    Sahin F; Sercan Z; Ertan Y; Ocakci S; Ay E; Vural F; Yuksel E; Tombuloglu M; Saydam G
    Hematology; 2007 Dec; 12(6):489-92. PubMed ID: 17852454
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Long-term complete haematological and molecular remission after allogeneic bone marrow transplantation in a patient with a stem cell myeloproliferative disorder associated with t(8;13)(p12;q12).
    Suzan F; Guasch G; Terre C; Garcia I; Bastie JN; Maarek O; Ribaud P; Gluckman E; Daniel MT; Pébusque MJ; Castaigne S
    Br J Haematol; 2003 Apr; 121(2):312-4. PubMed ID: 12694254
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Identification of a pure splenic form of chronic lymphocytic leukaemia.
    Dighiero G; Charron D; Debre P; Le Porrier M; Vaugier G; Follezou JY; Degos L; Jacquillat C; Binet JL
    Br J Haematol; 1979 Feb; 41(2):169-76. PubMed ID: 85456
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.